The trend toward larger deal sizes is likely to continue as companies seek to bolster their pipelines amid a looming patent ...

A tide change is rippling across healthcare. As industry leaders converged on San Francisco for the 2025 JP Morgan Healthcare conference, they echoed optimism about a renewed stability in healthcare, ...

This year’s JP Morgan struck a different tone than previous years—a very pleasant one, despite higher security anxieties ...

Digital health companies' plans focused on managing the impact of GLP-1 drugs, which have placed enormous pressure on health ...

The word on San Francisco’s famously hilly streets is that big pharma is ready to go shopping in 2025, following a flurry of ...

TransMedics Group Inc (TMDX) stock saw a modest uptick, ending the day at $67.03 which represents a slight increase of $5.96 or 9.76% from the prior close of $61.07. The stock opened at $61.47 and ...

Looking forward, we expect oil demand to rebound in the coming weeks, averaging 101.4 million barrels per day'.

Potential antitrust deregulation could foster a more favourable environment for larger M&A deals in 2025, though skepticism ...

In the tough market conditions last year, investors and big pharma companies were more likely to place their bets on later, clinical-stage companies. But local biotech leaders see signs of change in ...

In the wake of the 2024 U.S. elections, stakeholders in the life sciences and health care industry are intensely focused on the policy ...

Kaguya Komatsu has been named the first female CEO of J.P. Morgan Asset Management -Japan, succeeding Shoichi Ohkoshi, who ...